• 1. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

Introduction to 2-Hydroxy-6-(trifluoromethoxy)benzonitrile (CAS No: 1261852-86-1)

2-Hydroxy-6-(trifluoromethoxy)benzonitrile, identified by its Chemical Abstracts Service (CAS) number 1261852-86-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the benzonitrile class, characterized by the presence of a nitrile group (-CN) attached to a benzene ring. The structural features of this molecule, particularly the hydroxyl (-OH) and trifluoromethoxy (-OCH?CF?) substituents, endow it with unique chemical properties that make it a valuable intermediate in the synthesis of various bioactive molecules.

The hydroxyl group at the 2-position and the trifluoromethoxy group at the 6-position of the benzene ring play crucial roles in modulating the electronic and steric properties of the molecule. The hydroxyl group introduces polarity and potential hydrogen bonding capabilities, while the trifluoromethoxy group enhances lipophilicity and metabolic stability, making it an attractive moiety for drug design. These structural attributes have positioned 2-Hydroxy-6-(trifluoromethoxy)benzonitrile as a key building block in the development of novel therapeutic agents.

In recent years, there has been a surge in research focused on identifying and developing new compounds with enhanced pharmacological profiles. The benzonitrile scaffold is particularly well-studied due to its versatility in medicinal chemistry. Researchers have leveraged its core structure to develop molecules with activities ranging from anti-inflammatory to anticancer effects. The incorporation of electron-withdrawing groups such as nitrile and fluorinated alkoxy substituents further fine-tunes the pharmacokinetic properties of these derivatives, improving their bioavailability and target specificity.

One of the most compelling aspects of 2-Hydroxy-6-(trifluoromethoxy)benzonitrile is its potential application in the synthesis of small-molecule inhibitors targeting enzymes involved in critical biological pathways. For instance, studies have demonstrated its utility in generating derivatives that interact with kinases and phosphodiesterases, which are implicated in various diseases, including cancer and neurodegenerative disorders. The trifluoromethoxy group, in particular, has been shown to increase binding affinity and selectivity by modulating hydrogen bonding interactions and electronic effects.

Recent advancements in computational chemistry have further accelerated the discovery process for compounds like 2-Hydroxy-6-(trifluoromethoxy)benzonitrile. Molecular modeling techniques allow researchers to predict how different substituents will influence molecular interactions, enabling the rapid design of optimized analogs. This high-throughput virtual screening approach has been instrumental in identifying lead compounds for further experimental validation. The integration of machine learning algorithms into drug discovery pipelines has also enhanced our ability to predict pharmacological activity, making compounds like this one more accessible for therapeutic development.

The pharmaceutical industry has shown particular interest in benzonitrile derivatives due to their broad spectrum of biological activities. For example, modifications to the core benzonitrile structure have led to the identification of novel antimicrobial agents that combat resistant bacterial strains. Additionally, researchers have explored its potential as a precursor for developing antiviral drugs, particularly those targeting RNA-dependent RNA polymerases found in viruses such as influenza and hepatitis C. The structural flexibility of 2-Hydroxy-6-(trifluoromethoxy)benzonitrile allows for further functionalization, enabling chemists to tailor properties such as solubility, stability, and metabolic clearance.

In conclusion, 2-Hydroxy-6-(trifluoromethoxy)benzonitrile (CAS No: 1261852-86-1) represents a promising candidate for further exploration in medicinal chemistry. Its unique structural features—combining both polar and lipophilic moieties—make it an ideal starting point for synthesizing next-generation therapeutics. As research continues to uncover new applications for this compound and its derivatives, it is likely to remain a cornerstone in pharmaceutical innovation. The ongoing development of advanced synthetic methodologies and computational tools ensures that compounds like this will continue to play a pivotal role in addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)